Fujifilm VisualSonics has introduced a new imaging platform combining ultrasound and photoacoustic technologies in a single system aimed at preclinical research. The Toronto-based subsidiary says the Vevo F2 LAZR-X20 is the first ultrasound system to span ultrahigh to low frequencies for small animal imaging.

Designed for use in research areas such as oncology, cardiovascular biology, and neurobiology, the new platform enables noninvasive visualization of tissue structure and function. The system incorporates high-powered laser technology and operates within a 660–1320 nm wavelength range to support detailed tissue characterization, particularly of chromophores like lipids and collagen.

According to the company, the LAZR-X20 platform is intended to give researchers access to real-time, high-resolution imaging with improved depth penetration compared to earlier-generation systems.
“For more than two decades, FUJIFILM VisualSonics has been delivering ultrahigh-frequency ultrasound and photoacoustic imaging solutions to the scientific research community,” said Greg Nesbitt, vice president, global high-frequency at Fujifilm VisualSonics. “As a leader in the space, we saw an opportunity to expand the scope of questions that can be answered using photoacoustics.”

The company says the platform is particularly suited to studies requiring insights into tumor microenvironments, vascular biology, and molecular contrast agents.

Andrew Needles, director of product innovation at Fujifilm VisualSonics, said the technology “seamlessly” merges modalities in a way that could support new applications. “The new system provides excellent image quality and an expanded spectral range, providing researchers with comprehensive data for their imaging studies.”

Fujifilm VisualSonics is a subsidiary of Fujifilm Sonosite and part of Fujifilm Holdings Corporation, headquartered in Tokyo. The parent company operates across healthcare, electronics, and imaging sectors globally.

Ultrasound Homepage